Paul Tudor Jones's OCUL Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 614,378 shares of Ocular Therapeutix, Inc. (OCUL) worth $5.2 M, representing 0.01% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in OCUL, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 332,893 shares. Largest reduction occurred in Q2 2025, reducing 79,648 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Ocular Therapeutix (OCUL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ocular Therapeutix (OCUL) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +119,586 | Add 24.17% | 614,378 | $8.47 |
| Q4 2025 | +332,893 | Add 205.62% | 494,792 | $12.14 |
| Q3 2025 | +161,899 | New Buy | 161,899 | $11.69 |
| Q2 2025 | -79,648 | Sold Out | 0 | $0.00 |
| Q1 2025 | +79,648 | New Buy | 79,648 | $7.33 |
| Q2 2024 | -74,531 | Sold Out | 0 | $0.00 |
| Q1 2024 | -64,200 | Reduce 46.28% | 74,531 | $9.10 |
| Q4 2023 | -35,436 | Reduce 20.35% | 138,731 | $4.46 |
| Q3 2023 | -26,676 | Reduce 13.28% | 174,167 | $3.14 |
| Q2 2023 | +132,459 | Add 193.70% | 200,843 | $5.16 |
| Q1 2023 | -30,954 | Reduce 31.16% | 68,384 | $0.01 |
| Q4 2022 | +37,563 | Add 60.81% | 99,338 | $0.00 |
| Q3 2022 | +10,736 | Add 21.03% | 61,775 | $4.14 |
| Q2 2022 | +51,039 | New Buy | 51,039 | $4.02 |
| Q1 2022 | -40,987 | Sold Out | 0 | $0.00 |
| Q4 2021 | -53,725 | Reduce 56.72% | 40,987 | $6.98 |
| Q3 2021 | +94,712 | New Buy | 94,712 | $10.00 |
| Q1 2016 | -12,700 | Sold Out | 0 | $0.00 |
| Q4 2015 | +12,700 | New Buy | 12,700 | $9.37 |
| Q3 2015 | -17,663 | Sold Out | 0 | $0.00 |
| Q2 2015 | +17,663 | New Buy | 17,663 | $21.00 |
Paul Tudor Jones's Ocular Therapeutix Investment FAQs
Paul Tudor Jones first purchased Ocular Therapeutix, Inc. (OCUL) in Q2 2015, acquiring 17,663 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Ocular Therapeutix, Inc. (OCUL) for 21 quarters since Q2 2015.
Paul Tudor Jones's largest addition to Ocular Therapeutix, Inc. (OCUL) was in Q4 2025, adding 494,792 shares worth $6.01 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 614,378 shares of Ocular Therapeutix, Inc. (OCUL), valued at approximately $5.2 M.
As of the Q1 2026 filing, Ocular Therapeutix, Inc. (OCUL) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Ocular Therapeutix, Inc. (OCUL) was 614,378 shares, as reported at the end of Q1 2026.